Can zapping every tumor with radiation extend life? new trial aims to find out

NCT ID NCT05508464

Recruiting now Disease control Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This trial tests a precise type of radiation called SABR on all visible tumors in people with 11 or more metastases. Participants are randomly assigned to either standard palliative radiation or SABR to every tumor. The goal is to see if this aggressive approach improves overall survival, delays cancer growth, and maintains quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SABR (stereotactic ablative radiotherapy)
What this could lead to: If it works, this could show that targeting all tumors with precise radiation improves survival and quality of life for people with many metastases.
What could go wrong: This is a mid-stage trial with only 138 participants, so results may not apply to everyone. The treatment may cause side effects or not improve outcomes compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER

Contacts and locations

Locations

Centre Hospitalier de L'Universite de Montreal (CHUM)
RECRUITING

Montreal, Quebec, H2X 3E4, Canada
London Health Sciences Centre- London Regional Cancer Program
RECRUITING

London, Ontario, N6A 5W9, Canada
University Hospital of Zurich
RECRUITING

Zurich, 8091 zurich, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.